How much funding has Definium Therapeutics, Inc. Common Shares raised?

Definium Therapeutics, Inc. Common Shares has raised $371.0M in total funding, most recently a Corporate Round.

When was Definium Therapeutics, Inc. Common Shares founded?

Definium Therapeutics, Inc. Common Shares was founded in 2019.

Where is Definium Therapeutics, Inc. Common Shares headquartered?

Definium Therapeutics, Inc. Common Shares is headquartered in New York City, New York, United States.

What industry is Definium Therapeutics, Inc. Common Shares in?

Definium Therapeutics, Inc. Common Shares operates in Biotech, Healthcare.

How many employees does Definium Therapeutics, Inc. Common Shares have?

Definium Therapeutics, Inc. Common Shares has 11-50 employees.

Definium Therapeutics, Inc. Common Shares

IPO

Definium Therapeutics (Formerly MindMed) | Psychedelic Medicine

Public · New York City, United States · Founded 2019 · $371.0M raised

Biotech

Healthcare

Headquarters: New York City, New York
Employees: 11–50
Founded: 2019
Business Model: B2B
Website: definiumtx.com

Total Funding: $371.0M
Last Round: $225.0M Corporate RoundAug 2023
Rounds: 4
Type: Public

About

Definium Therapeutics (formerly MindMed, founded in 2019) is a clinical-stage biopharmaceutical company headquartered in New York developing psychedelic-inspired medicines for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder and is in Phase 3 trials for both GAD and major depressive disorder. The company rebranded from MindMed to Definium Therapeutics in January 2026.

Summary

Definium Therapeutics, Inc. Common Shares is a Biotech company based in New York City, United States, founded in 2019. It has raised $371.0M in total across 4 rounds, most recently a $225.0M Corporate Round round in Aug 2023.

LinkedIn X (Twitter)